<DOC>
	<DOCNO>NCT02533323</DOCNO>
	<brief_summary>This prospective study conduct evaluate efficacy safety profile first-line combined gemcitabine , oxaliplatin , Pegaspargase ( P-Gemox ) newly diagnose , nasal type , extranodal natural killer/T-cell lymphoma .</brief_summary>
	<brief_title>P-Gemox Regimen First-line Chemotherapy NK/T Lymphoma Patiens</brief_title>
	<detailed_description>Treatment P-Gemox dosage follow : day 1 , 30 min intravenous infusion 1250 mg/m2 gemcitabine ; day 1 , 2h intravenous infusion 85 mg/m2 oxaliplatin ; day 1 , deep intramuscular injection 2500 U/m2 PEG-ASP three different site . The regimen repeat every 2 week maximum six cycle . Stage IE/IIE patient underwent four cycle induction chemotherapy , follow involved-field radiotherapy get CR , PR SD . Three-dimensional conformal radiotherapy do linear accelerator 2.0 gray ( Gy ) per daily fraction 5-6 week . The involved- field radiation ( IFRT ) dose 50-56 Gy . Stage IIIE/IVE patient patient underwent least two cycle treatment unless disease progression unacceptable side effect , withdrawal patient consent . Primary tumor radiotherapy recommend achieve CR .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>newly diagnose ENKTL age:1880years lease one measurable lesion receive chemotherapy radiotherapy Eastern CooperativeOncology Group performance status 0 2 . Adequate hematologic function ( eg , white blood cell ≥ 3×10e9/l , neutrophil count ≥1.5×10e9/L , platelet count≥ 100×10e9/L ) , renal function ( eg , serum creatinine≤1.5 mg/dL creatinine clearance ≥50 mL minute ) , hepatic function ( e.g , total bilirubin≤ 2 time upper limit normal aspartate alanine transaminase level ≤ 3 time upper limit normal ) mismatch inclusion criterion systematic central nervous system involvement , previous concomitant malignancy coexist medical problem could cause poor compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NK/T-cell lymphoma</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>survival</keyword>
</DOC>